Nonsense mutation-containing genes (PTC-containing genes)

Nonsense mutation-containing genes represent a diverse group of genetic targets characterized by a point mutation that introduces a premature termination codon (PTC) into the coding sequence (Source: Nature Reviews Genetics, 2011). This premature stop signal typically leads to the production of truncated, non-functional proteins or triggers nonsense-mediated mRNA decay (NMD), which eliminates the transcript entirely (Source: NIH/NCBI). Such mutations are implicated in a wide array of inherited disorders, including Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF), where the lack of a specific functional protein drives the disease pathology (Source: Human Mutation, 2017). It is estimated that nonsense mutations account for approximately 11% of all described gene lesions causing human inherited disease (Source: HGMD). Pharmacological intervention primarily involves small molecules known as read-through agents, such as Ataluren, which modulate the ribosome's decoding site to allow the insertion of an amino acid at the PTC site (Source: EMA). This process enables the translation machinery to bypass the error and produce a full-length, functional protein, potentially mitigating the underlying cause of the genetic disease (Source: Journal of Medical Genetics). Current research also explores the inhibition of the NMD pathway to increase the availability of PTC-containing mRNA for read-through therapy (Source: Molecular Therapy). While promising, these therapies face challenges such as low read-through efficiency and the potential for off-target effects on natural stop codons (Source: Nucleic Acids Research).

Other names

Premature termination codon genesPTC-bearing genesNonsense-mediated decay targetsNonsense-mutated genes

Ribosomal read-through of premature termination codons (PTCs) to restore full-length protein synthesis